The management of overactive bladder syndrome

Marinkovic, Serge P.; Rovner, E.S.; Moldwin, Robert; Stanton, Stuart L.; Gillen, Lisa M.; Marinkovic, Christina M.

doi:10.1136/bmj.e2365

Cited by 54 publications

(43 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several meta-analyses of placebo-controlled trials of antimuscarinics in OAB syndrome indicate that it is well tolerated and efficacious in alleviating symptoms [24,25,26]. The meta-analyses also showed that there is a substantial placebo response [27]. Our meta-analysis compared mirabegron with tolterodine, proving that mirabegron was better than tolterodine in incontinence frequency; there were no statistically significant differences between the two groups in micturition and OAB-q.…”

Section: Discussionmentioning

confidence: 99%

The Role of Mirabegron in Overactive Bladder: A Systematic Review and Meta-Analysis

Duan

Cao

et al. 2014

Urol Int

View full text Add to dashboard Cite

Objective: To present a systematic review assessing the efficacy and safety of mirabegron for overactive bladder (OAB). Materials and Methods: A literature search was performed using the Cochrane Library, MEDLINE, EMBASE and Science Citation Index Expanded. The literature reviewed included meta-analyses, randomized and nonrandomized prospective studies. We utilized mean difference (MD) to measure the mean number of incontinence episodes and the mean number of micturitions, and OAB questionnaire (OAB-q) and odds ratio (OR) to measure adverse events rates. We used the Cochrane Collaboration's Review Manager 5.1 software for statistical analysis. Results: We identiﬁed six publications that strictly met our eligibility criteria. Meta-analysis of extractable data showed that mirabegron was more effective than placebo in treating OAB despite different drug dosages in the efficacy end points: mean number of incontinence episodes per 24 h (MD -0.54; 95% CI -0.63, -0.45; p = 0.001), mean number of micturitions per 24 h (MD -0.55; 95% CI -0.63, -0.47; p = 0.001), OAB-q (MD -4.49; 95% CI -6.27, -2.71; p = 0.001) and adverse events (OR 0.99; 95% CI 0.83, 1.19; p = 0.92). When compared to tolterodine, mirabegron was more effective in terms of mean number of incontinence episodes per 24 h (MD -0.25; 95% CI -0.43, -0.06; p = 0.009). However, there were no differences between mirabegron and tolterodine in mean number of micturitions per 24 h (MD -0.17; 95% CI -0.35, 0.01; p = 0.07) and OAB-q (MD -1.09; 95% CI -2.51, 0.33; p = 0.13). Mirabegron also had a lower adverse reaction rate (OR 0.9; 95% CI 0.8, 1.0; p = 0.04). Conclusions: In this diverse population, mirabegron was an effective and safe pharmacologic therapy for OAB.

show abstract

Section: Discussionmentioning

confidence: 99%

The Role of Mirabegron in Overactive Bladder: A Systematic Review and Meta-Analysis

Duan

Cao

et al. 2014

Urol Int

View full text Add to dashboard Cite

show abstract

“…It is reported to be common, with prevalence in adult females varying from 7.7% to 31.3% (Abrams et al 2009). OAB and its management can have a significant impact upon health-related quality of life (QoL) (Bartoli et al 2010, Sexton et al 2011, Marinkovic et al 2012. OAB symptoms are burdensome and can affect emotional well-being and work productivity (Irwin et al 2006, Coyne et One such modification proposed is reduction in caffeine intake (Gungor andBeji 2011, Rai et al 2012).…”

Section: Introductionmentioning

confidence: 99%

The Effect of Caffeinated Versus Decaffeinated Drinks on Overactive Bladder

Wells

Jamieson

Markham

et al. 2014

Journal of Wound, Ostomy &Amp; Continence Nursing

View full text Add to dashboard Cite

“…[1][2][3] OAB has been shown to have a negative effect on physical functioning and quality of life. With the aging population and increased life-expectancy there has been an increase in OAB diagnosis.…”

Section: Introductionmentioning

confidence: 99%

Publicly funded overactive bladder drug treatment patterns in Ontario over 15 years: An ecological study

Tadrous

Khuu

Mamdani³

et al. 2017

CUAJ

View full text Add to dashboard Cite

Introduction: Medication is an important option for patients with overactive bladder (OAB), with four different drugs approved over the last 10 years including the first non-anticholinergic treatment, mirabegron. We set out to describe the number and rate of users of medication for the management of OAB over the last 15 years among residents of Ontario, Canada covered by the public drug programs. Methods: We conducted a population-based, repeated cross-sectional study examining quarterly publically-funded prescription claims for OAB medications from January 2000 to June 2016 in Ontario, Canada. Results: We report two major changes in prescription patterns for OAB. The first was the rise of newer, more selective anticholinergics (tolterodine, solifenacin, and darifenacin) replacing oxybutynin. This led to a 54.8% reduction in the rate of users of oxybutynin over the study period from 10.4 users/1,000 beneficiaries in 2000 to 4.7 users/1,000 beneficiaries in 2016. Recently we saw the emergence of mirabegron as the most commonly prescribed treatment for OAB. By the final quarter of the observation period mirabegron was the most commonly used OAB treatment with 25.0% (n=19,411) of all OAB medication users in Ontario (n=77,660). Conclusion: Our findings highlight the rapid uptake of novel agents and a major shift in the treatment of OAB over the last 3 years.

show abstract

The management of overactive bladder syndrome

Cited by 54 publications

References 26 publications

The Role of Mirabegron in Overactive Bladder: A Systematic Review and Meta-Analysis

The Role of Mirabegron in Overactive Bladder: A Systematic Review and Meta-Analysis

The Effect of Caffeinated Versus Decaffeinated Drinks on Overactive Bladder

Publicly funded overactive bladder drug treatment patterns in Ontario over 15 years: An ecological study

Contact Info

Product

Resources

About